Literature DB >> 2877753

Cardiovascular pharmacology. II: The use of catecholamines, pressor agents, digitalis, and corticosteroids in CPR and emergency cardiac care.

C W Otto.   

Abstract

The Cardiovascular Pharmacology II panel met during the AHA National Conference on Standards and Guidelines for CPR and emergency cardiac care to consider the use of catecholamines, pressor agents, digitalis, and corticosteroids during advanced cardiac life support. During cardiac arrest, catecholamines and pressor agents have been shown to improve the rate of success of resuscitation. The useful properties of these drugs are mediated by strong alpha-adrenergic stimulation resulting in improved coronary perfusion. beta-Adrenergic stimulation during cardiac arrest is unimportant for resuscitation and potentially harmful. Studies have not demonstrated a difference between mixed agonists and alpha-agonists with respect to overall outcome. Consequently, the panel recommended that epinephrine continue to be the primary vasopressor for use during cardiac arrest. For cardiovascular support in the hemodynamically unstable patient, the panel recommended that drugs be chosen for specific pharmacologic actions that will allow the needed physiologic manipulation guided by objective hemodynamic measurements. The panel found that digitalis preparations and corticosteroids have very limited use in emergency cardiac care.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877753

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  1 in total

1.  Time to Epinephrine Administration and Survival From Nonshockable Out-of-Hospital Cardiac Arrest Among Children and Adults.

Authors:  Matthew Hansen; Robert H Schmicker; Craig D Newgard; Brian Grunau; Frank Scheuermeyer; Sheldon Cheskes; Veer Vithalani; Fuad Alnaji; Thomas Rea; Ahamed H Idris; Heather Herren; Jamie Hutchison; Mike Austin; Debra Egan; Mohamud Daya
Journal:  Circulation       Date:  2018-03-06       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.